logo
The ‘MAHA Report' calls for fighting chronic disease

The ‘MAHA Report' calls for fighting chronic disease

Gulf Today07-07-2025
David Hilzenrath,
Tribune News Service
The Trump administration has declared that it will aggressively combat chronic disease in America. Yet in its feverish purge of federal health programs, it has proposed eliminating the National Center for Chronic Disease Prevention and Health Promotion and its annual funding of $1.4 billion. That's one of many disconnects between what the administration says about health — notably, in the 'MAHA Report' that President Donald Trump recently presented at the White House — and what it's actually doing, scientists and public health advocates say. Among other contradictions:
• The report says more research is needed on health-related topics such as chronic diseases and the cumulative effects of chemicals in the environment. But the Trump administration's mass cancellation of federal research grants to scientists at universities, including Harvard, has derailed studies on those subjects.
• The report denounces industry-funded research on chemicals and health as widespread and unreliable. But the administration is seeking to cut government funding that could serve as a counterweight.
• The report calls for 'fearless gold-standard science.' But the administration has sowed widespread fear in the scientific world that it is out to stifle or skew research that challenges its desired conclusions.
'There are many inconsistencies between rhetoric and action,' said Alonzo Plough, chief science officer at the Robert Wood Johnson Foundation, a philanthropy focused on health.
The report, a cornerstone of President Donald Trump's 'Make America Healthy Again' agenda, was issued by a commission that includes Secretary of Health and Human Services Robert F. Kennedy Jr. and other top administration officials. News organisations found that it footnoted nonexistent sources and contained signs that it was produced with help from artificial intelligence. White House Press Secretary Karoline Leavitt described the problems as 'formatting issues,' and the administration revised the report. Trump ordered the report to assess causes of a 'childhood chronic disease crisis.' His commission is now working on a plan of action.
Spokespeople for the White House and Department of Health and Human Services did not respond to questions for this article.
The MAHA report says environmental chemicals may pose risks to children's health. Citing the National Institutes of Health, it said there's a 'need for continued studies from the public and private sectors, especially the NIH, to better understand the cumulative load of multiple exposures and how it may impact children's health.' Meanwhile, the administration has cut funding for related studies. For example, in 2020 the Environmental Protection Agency asked scientists to propose ways of researching children's exposure to chemicals from soil and dust. It said that, for kids ages 6 months to 6 years, ingesting particulates — by putting their hands on the ground or floor then in their mouths — could be a significant means of exposure to contaminants such as herbicides, pesticides, and a group of chemicals known as PFAS.
One of the grants — for almost $1.4 million over several years — went to a team of scientists at Johns Hopkins University and the University of California-San Francisco. Researchers gained permission to collect samples from people's homes, including dust and diapers. But, beyond a small test run, they didn't get to analyse the urine and stool samples because the grant was terminated this spring, said study leader Keeve Nachman, a professor of environmental health and engineering at Hopkins.
'The objectives of the award are no longer consistent with EPA funding priorities,' the agency said in a May 10 termination notice. Another EPA solicitation from 2020 addressed many of the issues the MAHA report highlighted: cumulative exposures to chemicals and developmental problems such as attention-deficit/hyperactivity disorder, obesity, anxiety, and depression. One of the resulting grants funded the Center for Early Life Exposures and Neurotoxicity at the University of North Carolina-Chapel Hill. That grant was ended weeks early in May, said the center's director, Stephanie Engel, a UNC professor of epidemiology.
In a statement, EPA press secretary Brigit Hirsch said the agency 'is continuing to invest in research and labs to advance the mission of protecting human health and the environment.' Due to an agency reorganisation, 'the way these grants are administered will be different going forward,' said Hirsch, who did not otherwise answer questions about specific grants. In its battle with Harvard, the Trump administration has stopped paying for research the NIH had commissioned on topics such as how autism might be related to paternal exposure to air pollution. The loss of millions of dollars of NIH funding has also undermined data-gathering for long-term research on chronic diseases, Harvard researchers said. A series of projects with names like Nurses' Health Study II and Nurses' Health Study 3 have been tracking thousands of people for decades and aimed to keep tracking them as long as possible as well as enrolling new participants, even across generations.
The work has included periodically surveying participants — mainly nurses and other health professionals who enrolled to support science — and collecting biological samples such as blood, urine, stool, or toenail clippings. Researchers studying health problems such as autism, ADHD, or cancer could tap the data and samples to trace potential contributing factors, said Francine Laden, an environmental epidemiologist at Harvard's TH Chan School of Public Health. The information could retrospectively reveal exposures before people were born — when they were still in utero — and exposures their parents experienced before they were conceived. Harvard expected that some of the grants wouldn't be renewed, but the Trump administration brought ongoing funding to an abrupt end, said Walter Willett, a professor of epidemiology and nutrition at the Chan school.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

5 years after COVID, pharma shares languish
5 years after COVID, pharma shares languish

Gulf Today

time2 days ago

  • Gulf Today

5 years after COVID, pharma shares languish

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative US market and potential 200% tariffs on pharma imports into the US. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved, reported Reuters. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying US policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs, Reuters reported. Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of US rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up — yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, US healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference.

Coca-Cola plans US cane sugar alternative after Trump push
Coca-Cola plans US cane sugar alternative after Trump push

Khaleej Times

time4 days ago

  • Khaleej Times

Coca-Cola plans US cane sugar alternative after Trump push

Coca-Cola on Tuesday said it would release a version of Coke in the United States made with US-grown real cane sugar, a move requested by President Donald Trump. "We're going to be bringing a Coke sweetened with US cane sugar into the market this fall, and I think that will be an enduring option for consumers," said CEO James Quincey on a call with analysts. The company currently uses high-fructose corn syrup (HFCS) for many of its US products — a sweetener that has long drawn criticism from Health Secretary Robert F. Kennedy Jr. and his "Make America Healthy Again" agenda. Trump last week said that the company had agreed to use cane sugar in the United States version of Coke. "This will be a very good move by them — You'll see. It's just better!" Trump wrote on Truth Social. Coca-Cola at the time did not confirm the move even if it said it appreciated Trump's "enthusiasm" for its brand. In announcing the new option, Quincey insisted that the main Coke product would still be made with corn syrup, with the cane sugar version offered as an alternative. Mexican Coke — which is made with cane sugar — is often sold at a premium in US stores and prized for its more "natural" flavour. The US president did not explain what motivated his push for the change, which would not impact his well-known favorite beverage, Diet Coke. Since his return to the White House, Trump has reinstalled a special button in the Oval Office that summons a helping of the sugar-free carbonated drink. HFCS became popular in the 1970s, with its use skyrocketing thanks to government subsidies for corn growers and high import tariffs on cane sugar. Any shift away from corn is likely to draw backlash in the Corn Belt, a Midwestern region that has been a stronghold of support for Trump. Both HFCS and sucrose (cane sugar) are composed of fructose and glucose, but differ at the structural level. Those differences don't appear to significantly affect health outcomes, according to research. Trump's preferred Diet Coke is sweetened with aspartame — a compound classified as a "possible carcinogen" by the International Agency for Research on Cancer (IARC).

AstraZeneca says to invest $50 billion in the US
AstraZeneca says to invest $50 billion in the US

Al Etihad

time4 days ago

  • Al Etihad

AstraZeneca says to invest $50 billion in the US

22 July 2025 11:25 LONDON (AFP)British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States amid a looming deadline of ramped-up tariffs from Washington.A large chunk of the funds will go toward building a multi-billion-dollar manufacturing centre in Virginia, the company said in a statement, adding that it expects 50 percent of its revenue to come from the United States by 2030."Today's announcement underpins our belief in America's innovation in biopharmaceuticals," the statement quoted CEO Pascal Soriot as President Donald Trump has opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to his sweeping levies on imports from trading ordered an investigation launched into pharmaceutical imports, suggesting that levies could reach up to 200 United States is a key market for the pharmaceutical industry, and AstraZeneca had already announced in April that it had begun transferring part of its European production to the United States. "For decades Americans have been reliant on foreign supply of key pharmaceutical products," US Commerce Secretary Howard Lutnick said in a added that the new tariffs are focused on "ending this structural weakness."The announcement included a new factory in Virginia, which will be the company's "largest single manufacturing investment." Other major pharmaceutical companies, which had been exempt from tariffs for 30 years, have, in recent months, begun shifting investment and production to the United States.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store